Results 171 to 180 of about 1,652 (181)

Combined inhibition of WEE1 by AZD1775 synergistically enhances CX-5461 mediated DNA damage and induces cytotoxicity in glioblastoma

Tissue and Cell
Glioblastoma (GBM) is an extremely aggressive type of central nervous system tumors that poses treatment challenges due to its resistance to DNA-damaging therapies. G-quadruplexes (G4) are non-canonical DNA structures involved in genomic stability and transcription regulation, and they have emerged as potential therapeutic targets. Originally developed
Meng Cheng, Rui Wang, Ying Pang, Xu Chen, Jing Zhang, Chunlong Zhong   +5 more
openaire   +2 more sources

Preclinical Evaluation of the Combination of AZD1775 and Irinotecan Against Selected Pediatric Solid Tumors: A Pediatric Preclinical Testing Consortium Report

Pediatric Blood and Cancer, 2020
Richard G Gorlick, Malcolm A Smith, Peter J. Houghton   +2 more
exaly  

WEE1 kinase inhibitor, adavosertib (AZD1775), as a novel potential therapeutic strategy in advanced adrenocortical carcinoma

Endocrine Abstracts, 2023
Mariangela Tamburello, Silviu Sbiera, Weber Justus, Juliane Lippert, Mario Detomas, Marc Philipp Schauer, Hanna Urlaub, Sonja Steinhauer, Otilia Kimpel, Laura-Sophie Landwehr, Hantel Constanze, Sandra Sigala, Cristina Ronchi, Michael Hudecek, Kiseljak-Vassiliades Katja, Martin Fassnacht, Barbara Altieri   +16 more
openaire   +1 more source

Wee1 Kinase Inhibitor AZD1775 Potentiates CD8+ T Cell-Dependent Antitumour Activity via Dendritic Cell Activation Following a Single High Dose of Irradiation

Medical Oncology, 2020
Zhiyong Yuan, Zhen Tao
exaly  

AZD1775: effect of monotherapy or EDP-M combination in the treatment of ACC preclinical models

Endocrine Abstracts
Nozza, Emma, Catalano, Rosa, di, Muro Genesio, di, Bari Sonia, Lopez, Gianluca, Marra, Giusy, Esposito, Emanuela, Mangili, Federica, Treppiedi, Donatella, Battistin, Michele, Mantovani, Giovanna, Peverelli, Erika   +11 more
openaire   +1 more source

Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer

Journal of Clinical Oncology, 2019
Mark M Zalupski, Theodore S Lawrence, Jonathan Maybaum   +2 more
exaly  

An Aqueous Normal-Phase Chromatography Coupled With Tandem Mass Spectrometry Method for Determining Unbound Brain-to-Plasma Concentration Ratio of AZD1775, a Wee1 Kinase Inhibitor, in Patients With Glioblastoma

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016
Patricia M. Lorusso, Nader Sanai, Xun Bao   +2 more
exaly  

Phase I Study Evaluating WEE1 Inhibitor AZD1775 as Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors

Journal of Clinical Oncology, 2016
Jan H M Schellens, Anna C Pavlick, Raoul Tibes   +2 more
exaly  

Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months

Journal of Clinical Oncology, 2016
Serena Marchetti, Jan H M Schellens, Erik van Werkhoven   +2 more
exaly  

Augmentation of the Therapeutic Efficacy of WEE1 Kinase Inhibitor AZD1775 by Inhibiting the YAP–E2F1–DNA Damage Response Pathway Axis

FEBS Open Bio, 2018
Naoyuki Nishiya, Yoshimasa Uehara
exaly